AGIOAgios Pharmaceuticals, Inc.

AGIO Stock Price, Valuation & Chart | Agios Pharmaceuticals, Inc.

Compare

$34.130-0.08 (-0.23%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology AGIO intrinsic value AGIO calculated fair value vs price

Overview Financials Dividends Ratios

AGIO Historical price chart

AGIO Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization2.04B

PE Ratio-4.71

EPS-7.25

Trading Volume650.84K

Today's High/Low34.75/33.53

Dividend Yield0.00

52 Week High/Low46.0/22.24

Shares Outstanding59.70M

AGIO Financial Statement

AGIO Analyst ratings

AGIO Analysis & performance metrics

AGIO Company profile

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of…

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers PYRUKYND (mitapivat) an activator of both wild-type and a variety of mutant pyruvate kinase, PK, enzymes for the treatment of hemolytic anemias; and AG-946 that is in Phase I clinical study…

AGIO Management team

Name

Position

Shin-San Su Ph.D.

Co-Founder

Tsveta Milanova

Chief Commercial Officer

Craig B. Thompson M.D.

Co-Founder

Brian M. Goff M.B.A.CEO

Chief Executive Officer & Director

Lewis clayton Cantley Ph.D.

Co-Founder

Sarah Gheuens M.D., Ph.D.

Chief Medical Officer and Head of Research & Development

T. J. Washburn

Vice President, Controller & Principal Accounting Officer

Cecilia JonesCFO

Chief Financial Officer

Name

Position

Shin-San Su Ph.D.

Co-Founder

Tsveta Milanova

Chief Commercial Officer

Craig B. Thompson M.D.

Co-Founder

Brian M. Goff M.B.A.CEO

Chief Executive Officer & Director

Lewis clayton Cantley Ph.D.

Co-Founder

Sarah Gheuens M.D., Ph.D.

Chief Medical Officer and Head of Research & Development

T. J. Washburn

Vice President, Controller & Principal Accounting Officer

Cecilia JonesCFO

Chief Financial Officer

Management Team

Shin-San Su Ph.D.

Co-Founder

Tsveta Milanova

Chief Commercial Officer

Craig B. Thompson M.D.

Co-Founder

Brian M. Goff M.B.A.CEO

Chief Executive Officer & Director

Lewis clayton Cantley Ph.D.

Co-Founder

Sarah Gheuens M.D., Ph.D.

Chief Medical Officer and Head of Research & Development

T. J. Washburn

Vice President, Controller & Principal Accounting Officer

Cecilia JonesCFO

Chief Financial Officer

Management

Shin-San Su Ph.D.

Co-Founder

Tsveta Milanova

Chief Commercial Officer

Craig B. Thompson M.D.

Co-Founder

Brian M. Goff M.B.A.CEO

Chief Executive Officer & Director

Lewis clayton Cantley Ph.D.

Co-Founder

Sarah Gheuens M.D., Ph.D.

Chief Medical Officer and Head of Research & Development

T. J. Washburn

Vice President, Controller & Principal Accounting Officer

Cecilia JonesCFO

Chief Financial Officer

Total 8 executives

AGIO Frequently asked questions

What is Agios Pharmaceuticals, Inc. (AGIO) Stock Price?

Current stock price of Agios Pharmaceuticals, Inc. (AGIO) stock is $34.130. The stock price is -0.23% lower in the session. The intraday range can be seen from this page. Volume of Agios Pharmaceuticals, Inc. (AGIO) stock is 650.84K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Agios Pharmaceuticals, Inc. (AGIO) stock price going up or down today?

The stock price of Agios Pharmaceuticals, Inc. (AGIO) can change with earnings, company news, and overall market sentiment. Agios Pharmaceuticals, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Agios Pharmaceuticals, Inc. stock expensive at its current price?

Whether Agios Pharmaceuticals, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for AGIO on this page is -4.71. EPS on this page is -7.25. Compare those figures with peers and growth expectations before deciding if the current Agios Pharmaceuticals, Inc. price is justified.

How has the stock price of Agios Pharmaceuticals, Inc. (AGIO) performed historically?

Historical performance for Agios Pharmaceuticals, Inc. (AGIO) is shown on the price chart on this page. Review multi-period moves alongside volume to see how AGIO reacted to past earnings and market events.

Should I buy Agios Pharmaceuticals, Inc. (AGIO) stock, at this price?

Buying Agios Pharmaceuticals, Inc. (AGIO) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.